Oscar Health, Inc. (OSCR) shares soared 5.29% in pre-market trading on Tuesday, despite reporting disappointing second-quarter results for 2025. The health insurance technology company's stock rally appears to be driven by its revised and potentially optimistic outlook for the full year 2025.
According to the company's preliminary financial results, Oscar Health reported a Q2 adjusted EBITDA of -$120 million, falling short of the IBES estimate of $116.9 million. The net income for the quarter stood at a substantial loss of $228 million. Despite these underwhelming figures, investors seem to be focusing on the company's forward-looking projections.
Oscar Health revised its 2025 guidance, now anticipating annual revenue between $12.0 billion and $12.2 billion. Additionally, the company expects a Medical Loss Ratio of 86.0% to 87.0% for 2025. These projections appear to have instilled confidence in investors, potentially indicating improved operational efficiency and growth prospects for the company. The market's positive reaction suggests that these forward-looking metrics may have exceeded previous expectations, overshadowing the current quarter's weak performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.